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Antibodies against T cell checkpoint molecules have started to revolutionize cancer treatment. Nevertheless,
less than half of all patients respond to these immunotherapies. Recent work supports the potential value of
biomarkers that predict therapy outcome and inspires the development of assay systems that interrogate
other aspects of the cancer-immunity cycle.Developments in T cell checkpoint-based
cancer immunotherapies are occurring at
a mind blowing pace. Following the
demonstration of improved survival in
melanoma patients treated with anti-
CTLA4, the clinical value of targeting the
PD-1 axis has been demonstrated in tu-
mor types as diverse as melanoma, non-
small cell lung cancer, bladder cancer,
andHodgkin’s lymphoma. Although these
clinical data are extraordinary, the dearth
of biomarkers that can identify those pa-
tients that are most likely to benefit from
these therapies forms a limitation. Identifi-
cation of such biomarkers would avoid
treatment-related toxicity and cost in pa-
tients that are unlikely to benefit and
should also increase our understanding
of modes of action of immunotherapy
and thereby identify potential combina-
tion therapies.
A recent publication describes a ge-
netic basis for clinical response to
CTLA-4 blockade in melanoma patients,
allowing the discrimination of responding
from nonresponding patients prior to ther-
apy (Snyder et al., 2014). Furthermore,
work by a number of groups describes
aspects of the tumor microenvironment
that may be of value to predict response
to blockade of the PD-1-PD-L1 axis
(Herbst et al., 2014; Powles et al., 2014;
Tumeh et al., 2014).
Mutated peptides resulting from DNA
mutations are recognized by CD8+ (Rob-
bins et al., 2013; van Rooij et al., 2013)
and CD4+ T cells (Linnemann, et al.,
2014) in a large fraction of melanoma pa-
tients, and these neo-antigen-specific
T cell responses are likely to contribute
to the clinical effects of cancer immuno-
therapy (Heemskerk et al., 2013). To
analyze potential effects of cancer ge-
nomes on response to immunotherapy,12 Cancer Cell 27, January 12, 2015 ª2015 ESnyder et al. (2014) characterized the
tumor mutational landscape from mela-
noma patients treated with the anti
CTLA-4 antibody ipilimumab. Within
both a discovery and validation cohort, a
higher mutational load was associated
with long-term benefit. Overall survival
was significantly higher in patients with a
high mutational load in the discovery
cohort, and a nonsignificant trend toward
improved survival was seen in the valida-
tion cohort. These data provide some
support for the hypothesis that immuno-
therapy is particularly effective in highly
mutagenized tumors, but analysis of
larger cohorts will be required to firm up
this conclusion.
Next, the authors developed a bioinfor-
matics pipeline to predict the neo-epi-
topes that may be recognized by CD8+
T cells, as based on predicted binding to
patient-specific HLA class I alleles, pre-
dicted immunogenicity, and similarity to
known T cell epitopes. Strikingly, the
authors subsequently identified 101 four
amino acid (tetrapeptide) motifs within
the predicted nonameric neo-epitopes
that were shared between patients with
a long-term clinical benefit but absent in
tumors of patients with no or minimal clin-
ical benefit. Furthermore, simulations us-
ing five models showed that the observed
correlation between the identified signa-
ture and clinical course was very unlikely
to have arisen by chance. Perhaps most
strikingly, the predictive value of this
signature was confirmed in an indepen-
dent validation cohort.
How may the predictive value of the
identified tetrapeptide motifs be ex-
plained? On the basis of their data,
Snyder et al. (2014) propose that mutated
peptides that contain one of these tetra-
peptide motifs are targets for autologouslsevier Inc.T cells. In support of this, the authors
document T cell reactivity against two
such peptides following in vitro restimula-
tion of autologous T cells. Nevertheless, a
number of aspects of the proposed role of
tetrapeptide containing epitopes as can-
cer rejection antigens remain to be eluci-
dated. First, while different HLA alleles
can bind peptides with similar sequences,
the observation that the tetrapeptide
motifs do not show an HLA restriction is
unexpected. Second, a given tetrapep-
tide sequence is observed to occur in
different positions in different mutated
peptides, arguing against a fixed role of
the tetrapeptide motif in T cell receptor
(TCR) recognition. It may be reasoned
that the human TCR repertoire is biased
toward recognition of certain motifs that
are ‘‘foreign’’, and some of the motifs
identified by Snyder et al. (2014) are
enriched in known T cell epitopes
derived from human pathogens. How-
ever, because similarity to known T cell
epitopes is part of the bioinformatics
pipeline used to identify candidate neo-
epitopes, this is perhaps not entirely
unexpected. As a side note, to determine
whether the identified motifs may be
characteristic of nonhuman genomes,
we calculated the occurrence of the
tetrapeptide motifs in the human genome
versus a series of bacterial genomes
(n = 14). This analysis provides little evi-
dence for substantial overrepresentation
of the identified tetrapeptide motifs in
nonhuman genomes (C.K., unpublished
data).
If the human neo-antigen specific T cell
response would be focused on mutated
peptides that contain one of the tetrapep-
tide motifs, one would expect such motifs
to be frequently observed in validated
neo-antigens identified in other studies.
AB
Figure 1. Neo-Antigen Signatures and Other Biomarkers within the Cancer-Immunity Cycle
(A) The percentage of nonameric peptides containing one of the tetrapeptide motifs within either documented neo-epitopes (left, n = 13) or nonameric peptides
derived from the human proteome predicted to bind with an affinity of% 500nM to HLA-A*01:01, A*02:01, A*03:01, B*07:02, or B*08:01 (right, n = 2,327,696). The
blue chart piece represents the percentage of epitopes containing one of the motifs.
(B) Opportunities for biomarker discovery (blue) in the cancer-immunity cycle.
Reprinted and adapted from Chen and Mellman (2013) with permission from Elsevier.
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peptide motifs in a set of nonameric
neo-antigens in human melanoma (Rob-
bins et al., 2013; van Buuren et al., 2014;
van Rooij et al., 2013) shows that 1 out
of 13 neo-antigens contained one of the
101 tetrapeptide motifs (Figure 1A, left).
As a comparison, the frequency of these
motifs within nonameric peptides that
are predicted to bind to HLA class I in
the entire human genome is approxi-
mately 2% (Figure 1A, right). Obviously,
the list of documented neo-epitopes is
presently too small to tell whether tetra-
peptide motifs occur more often in mela-noma neo-antigens than would be
expected by chance. However, this analy-
sis does suggest that T cell recognition of
mutated epitopes that contain one of the
identified tetrapeptide motifs is not a
dominant component of the neo-antigen
specific T cell response in human mela-
noma. It will be exciting to further dissect
by which mechanism the occurrence of
the tetrapeptide signature predicts the
likelihood of response to CTLA-4 target-
ing in future studies.
The data from Snyder et al. (2014) pro-
vide strong evidence that genomic char-
acteristics of human tumors can formCancer Cell 2potential biomarkers in cancer immuno-
therapy. At the same time, it is apparent
that information on other aspects of the
interaction between the T cell-based
immune system and tumor cells (‘‘the
cancer-immunity cycle’’; Chen and Mell-
man, 2013) will provide relevant informa-
tion. Using cancer cells as a starting point
(Figure 1B), a first set of biomarkers can
be envisioned that describe whether the
tumor is likely to contain antigens that
may be recognized by T cells, be it re-
flected by either the size of the foreign
antigen space generated by mutations
and viral antigens or the type of signature7, January 12, 2015 ª2015 Elsevier Inc. 13
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ond, it may be useful to consider bio-
markers that provide a simple measure
of general immune status, thereby indi-
cating whether a patient has the capacity
to mount a relevant T cell response. Third,
the accumulation of a CD8+ T cell pool
within the tumor and a bias of this T cell
pool toward a restricted number of TCR
clonotypes are likely to provide substan-
tial predictive value, as demonstrated by
Ribas and colleagues in melanoma pa-
tients treated with anti-PD1 (Tumeh
et al., 2014). Finally, expression of inhibi-
tory molecules such as PD-L1 within the
tumor microenvironment can both pro-
vide information on an ongoing immune
dialog and potential targets for therapeu-
tic intervention. Indeed, expression of
PD-L1 on tumor infiltrating immune cells
has recently been put forward as a
possible biomarker in anti-PD-L1 treat-
ment (Herbst et al., 2014; Powles et al.,
2014).
Looking forward, a coordinated effort to
assess the value of both genetic and
nongenetic biomarkers that address
different aspects of the cancer-immunity14 Cancer Cell 27, January 12, 2015 ª2015 Ecycle in T cell checkpoint blockade will
allow the field to integrate information on
individual aspects of tumor-immune inter-
action. In addition, such analyses should
yield biomarkers that—either alone or in
combination—will allow the development
of rationally designed combination thera-
pies for individual patients.ACKNOWLEDGMENTS
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